# METHODOLOGY USED BY IPSEN IN PREPARING THE DISCLOSURE OF SUPPORT AND SERVICES PROVIDED TO PATIENT ORGANISATIONS IN 2024

#### 1. INTRODUCTION

Ipsen's goal is to work for and with patients. To achieve this, in addition to making available to them all our science and innovative medicines, we develop awareness and educational projects within the different therapeutic areas in which we are present. These initiatives are part of our commitment to patients, their families and society.

Patients are the pillar of healthcare. From prevention and awareness, through research and development, regulatory and evaluation processes, to service design and measurement of results. Patients bring forth their knowledge and experience of living with a condition and patient representatives ensure the voices of their communities are heard, sharing how the disease affects them, what is really important to them, their families and their carers. Appropriate embedding of the patient perspective throughout the medicine's life cycle has the potential to co-create and co-develop better healthcare management and patient outcomes, providing greater efficiency in healthcare and patient care.

Ipsen discloses annually information about the patient organisations to which it provides support or with whom it has engaged to provide contracted services. As a member of EFPIA, in line with the EFPIA Code of Practice, Ipsen discloses this information at a European level in both its local and corporate websites.

This transparency initiative aims to generate credibility and trust in the pharmaceutical industry as a whole and in the collaborations that exist between pharmaceutical companies and patient organisations. It informs about the different forms of collaboration that exist between pharmaceutical companies and patient organisations and demonstrates its interest in this being carried out respecting the strictest ethical principles of professionalism and responsibility.

#### 2. **DEFINITIONS**

**Patient Organisation (PO):** non-for-profit legal person/entity (including the umbrella organisation to which it belongs), mainly composed of patients and/or caregivers, that represents and/or supports the needs of patients and/or caregivers.

#### 3. KIND OF SUPPORT AND SERVICES PROVIDED TO POs

With the aim of increasing disease awareness and education, as well as helping to improve patient care and health-related quality of life, Ipsen can both support patient organisation's activities or contract their expert services upon a related legitimate need. Context is always non-promotional without mention of any specific products. Ipsen can support a patient organisation to organize disease awareness activities and pathology related educational events. These have the aim of increasing awareness of a disease or diseases, favoring prevention and early detection for improved patient outcomes and to provide health educational information on that disease and its management. Ipsen may also contract patient organisation representatives as speakers to reflect the patients' experience living with a medical condition or as consultants to obtain their expert advice on unmet patient needs and expectations as well as experience living with a medical condition to inform Ipsen's strategy. Appropriate inclusion of the patient's perspective across the life cycle of the medicine has the potential to co-create and co-develop better health care management and patient outcomes, delivering greater efficiencies in healthcare utilization.

#### 4. DISCLOSURE'S SCOPE

This disclosure exercise includes all types of collaborations between Ipsen and patient organisations which business address, place of incorporation or primary place of operation is in Europe. Ipsen must disclose a list of POs to which it provides financial support and/or significant indirect/non-financial support or with whom it has engaged to provide contracted services for Ipsen. This disclosure must include a description of the nature of the support or services provided that is sufficiently complete to enable the average reader to form an understanding of the nature of the support or the arrangement without the necessity to divulge confidential information.

In addition to the name of the PO, for support provision the monetary value of financial support and of invoiced costs and the non-monetary benefit that the PO receives when the non-financial support cannot be assigned to a meaningful monetary value are included. For contracted services the total amount paid per PO over the reporting period is included. Each reporting period covers a full calendar year.

# 5. CROSS-BORDER ACTIVITIES

Ipsen has defined an internal procedure for the publication of cross-border collaborations. All collaborations with patient organisations shall be published in Ipsen's report pertaining to the country where the patient organisation is registered, including those made by the parent company and other Ipsen affiliates.

# 6. IDENTIFICATION OF THE RECIPIENTS

Each recipient of the transfer of value is identified through the name of the patient organisation.

# 7. INFORMATION COLLECTION

The consolidation of the information has been carried out using Ipsen corporate applications. The different existing sources of information at the local and corporate level have been consolidated, including cross-border collaborations.

## 8. QUALITY CHECKS

Prior to publication, Internal validation of the information to be published was carried out.

## 9. CURRENCY

Ipsen will disclose the amounts using the local currency of the country where the disclosure is made, even if the payment of the ToV has been done in a different currency. The disclosed amounts will be in Pounds for the UK, and in Euros for Ireland.

# **10.VAT INCLUDED OR EXCLUDED**

For the UK and Ireland, where possible, the NET amount is disclosed. If VAT cannot accurately be excluded, the Gross amount is disclosed.

## **11.DATE OF PUBLICATION**

Aligned with EFPIA Ipsen discloses all the relevant collaborations by the 30th of June for the previous year.

The date used for the collection and publication of collaborations related to disease awareness or educational events is the starting date of the activity or meeting. In the case of contracts for the provision of services linked to a meeting or event, the date used is also the starting date of the activity or meeting. For non-meeting service contracts, the date used for collecting and publishing the information is the invoice date.

For multi-year contracts the value transfer part corresponding to the year 2024 will be included.

### **12.DISCLOSURE PLATFORM**

The information shall be published in Ipsen's corporate website under Support to patients and patient organizations: <u>Governance at Ipsen | Upholding Ethical Business Practices</u>. In addition, affiliates shall also disclose it in their country websites.

#### **13.DISCLOSURE LANGUAGE**

The report is published in English for the UK and Ireland.

## **14.LEGAL NOTICE**

We use a combination of automated systems, standardised procedures and manual data entry to collect the relevant information to be disclosed. The information published reflects Ipsen's good faith and best efforts to comply with the provisions of article 24 of the EFPIA Code of Practice. In the event that, despite our best efforts to ensure a publication that accurately reflects the collaborations carried out, we have failed to include correct and complete information, we will investigate and provide an appropriate response if the information is incorrect.